Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Asthma-IV: Nursing Management

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma III: Clinical Manifestations

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

"Severe-controlled" asthma 4 years later: is it still controlled?

The Journal of asthma : official journal of the Association for the Care of Asthma·2020

Same author

Severe and non-severe asthma in the community: A large electronic database analysis.

Respiratory medicine·2017

Same author

[Posture-dependent refractory hypoxemia].

Harefuah·2011

Same author

Thrombolytic therapy for acute life-threatening pulmonary thromboembolism in a pregnant woman.

The Israel Medical Association journal : IMAJ·2008

Same author

[Reasons for the gap between asthma in reality and GINA guidelines].

Harefuah·2007

Same author

[Acute eosinophilic pneumonia: a potentially fatal disease under a mask of acute community-acquired bacterial pneumonia].

Harefuah·2006

Search research articles

Related Experiment Video

Updated: May 22, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

[Perspectives in future asthma therapy].

Shabtai Varsano¹

¹Asthma Care and Education Unit, Department of Pulmonary Medicine, Sapir Medical Center, Meir Hospital Kfar Saba, and Sackler Faculty of Medicine, Tel Aviv University, Israel. Varsanos@clalit.org.il

|May 24, 2012

Summary

Future asthma treatments will focus on personalized medicine and advanced delivery systems for difficult-to-treat patients, improving outcomes for all asthmatics. These innovations aim to overcome challenges in current asthma management.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 22, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

Pulmonology and Respiratory Medicine
Pharmacology and Therapeutics
Immunology

Context:

A significant portion of asthma patients (5-10%) exhibit resistance to maximal medical therapies, including systemic steroids.
These non-responsive asthmatics account for a disproportionately high healthcare cost (80% of total asthma management expenses).
Other asthmatics face challenges with medication non-compliance or severe adverse effects from existing treatments.

Purpose:

To explore emerging trends and future directions in asthma therapy.
To identify novel treatment strategies addressing unmet needs in specific asthma patient subgroups.
To project the clinical implications of these advancements over the next 5-15 years.

Summary:

Future asthma management will involve immunomodulation, targeting key receptors and inflammatory mediators.
Personalized pharmacogenetics will enable custom-made medications.
Innovations include advanced immunotherapy, smart inhalers, sophisticated aerosol delivery, and bronchial thermoplasty.

Impact:

These advancements promise improved therapeutic outcomes for difficult-to-treat asthma populations.
The entire asthma patient community is expected to benefit from future therapeutic achievements.
Anticipated clinical integration of these novel approaches within the next decade to 15 years.